Both studies underscore the potential diagnostic utility of ENHO and Adropin in distinguishing cancer patients from healthy individuals, with the high sensitivity and specificity of Adropin in endometrial cancer reinforcing its role as a clinically relevant biomarker. The gene discussed is ENHO; the disease is endometrial cancer.